RCKT Stock Overview
Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rocket Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.20 |
| 52 Week High | US$32.53 |
| 52 Week Low | US$12.62 |
| Beta | 1.09 |
| 11 Month Change | -18.81% |
| 3 Month Change | -24.39% |
| 1 Year Change | -37.86% |
| 33 Year Change | -39.93% |
| 5 Year Change | -26.14% |
| Change since IPO | 13.60% |
Recent News & Updates
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?
Sep 23
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
Sep 15Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Jun 28Recent updates
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?
Sep 23Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
Sep 15Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Jun 28We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Jun 09Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Apr 05Rocket Pharmaceuticals' Promising Path In Gene Therapy
Mar 01Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth
Nov 07Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Oct 03Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate
Aug 25We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Jul 22Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs
Jul 08Rocket Pharma: Poised For Growth In The Rare Disease Space
Jun 30Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside
Jan 30We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Nov 09Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes
Oct 01Rocket earns Evercore nod after positive data for rare genetic disease
Dec 17Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial
Dec 09Shareholder Returns
| RCKT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.9% | 4.0% | 2.0% |
| 1Y | -37.9% | 18.0% | 32.4% |
Return vs Industry: RCKT underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: RCKT underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| RCKT volatility | |
|---|---|
| RCKT Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RCKT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RCKT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 268 | Gaurav Shah | www.rocketpharma.com |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy.
Rocket Pharmaceuticals, Inc. Fundamentals Summary
| RCKT fundamental statistics | |
|---|---|
| Market cap | US$1.29b |
| Earnings (TTM) | -US$258.08m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs RCKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCKT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$258.08m |
| Earnings | -US$258.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.83 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RCKT perform over the long term?
See historical performance and comparison